Dr. Subrata ChakravartyMD · Anesthesiology & Addiction Medicine
Menu

PresentationsHepatitis C

ECHO+ Liver 9th Annual Congress, 2026

Treating HCV in an Urban Vulnerable Population

Bridging the gaps from diagnosis to cure: how an addiction medicine clinic, supported by ECHO+, brings hepatitis C treatment to people the system usually misses.

View slides (PDF)
Presented at
ECHO+ Liver 9th Annual Congress
Location
Canada
Year
2026
Format
Talk
  1. Slide 1 of 19: Treating HCV in an Urban Vulnerable Population
  2. Slide 2 of 19: Treating HCV in an Urban Vulnerable Population
  3. Slide 3 of 19: Treating HCV in an Urban Vulnerable Population
  4. Slide 4 of 19: Treating HCV in an Urban Vulnerable Population
  5. Slide 5 of 19: Treating HCV in an Urban Vulnerable Population
  6. Slide 6 of 19: Treating HCV in an Urban Vulnerable Population
  7. Slide 7 of 19: Treating HCV in an Urban Vulnerable Population
  8. Slide 8 of 19: Treating HCV in an Urban Vulnerable Population
  9. Slide 9 of 19: Treating HCV in an Urban Vulnerable Population
  10. Slide 10 of 19: Treating HCV in an Urban Vulnerable Population
  11. Slide 11 of 19: Treating HCV in an Urban Vulnerable Population
  12. Slide 12 of 19: Treating HCV in an Urban Vulnerable Population
  13. Slide 13 of 19: Treating HCV in an Urban Vulnerable Population
  14. Slide 14 of 19: Treating HCV in an Urban Vulnerable Population
  15. Slide 15 of 19: Treating HCV in an Urban Vulnerable Population
  16. Slide 16 of 19: Treating HCV in an Urban Vulnerable Population
  17. Slide 17 of 19: Treating HCV in an Urban Vulnerable Population
  18. Slide 18 of 19: Treating HCV in an Urban Vulnerable Population
  19. Slide 19 of 19: Treating HCV in an Urban Vulnerable Population

1 / 19

Open PDF Download

Key messages

  1. Specialist support can travel: treatment decisions can be made without every patient navigating a separate liver-care pathway.

  2. Continuity is the main challenge. Offering treatment is not enough if follow-up is interrupted.

  3. Substance use, mental health, housing and social circumstances shape engagement in care.

  4. The clinical plan works only when the care pathway can withstand real-life disruption.

Prepared for healthcare professionals. These presentations summarize clinical evidence and experience for colleagues. They are not advice about your own care; please speak with your physician.

More work

All presentations
Title slide: Kamini Use in Canada

Addiction medicineISAM 2026 · Rotterdam, 2026

Kamini Use in Canada

An emerging substance of concern identified in Alberta: a herbal product that can carry opium-derived opioids, dependence and lead toxicity.

15 slidesE-poster

View presentation
Title slide: Emerging Fentanyl Analogues & Veterinary Tranquillisers

Toxic drug supplyISAM 2026 · Rotterdam, 2026

Emerging Fentanyl Analogues & Veterinary Tranquillisers

Urine drug screening gaps and preventative strategies in Alberta: what routine screens miss in a fast-changing drug supply, and how clinics can respond.

12 slidesE-poster

View presentation